Get the Stockscreener App
90.17
0.66%
0.635
Nuvalent Inc stock is traded at $90.17, with a volume of 121.47K.
It is up +0.66% in the last 24 hours and down -14.11% over the past month.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$89.53
Open:
$88.7
24h Volume:
121.47K
Relative Volume:
0.24
Market Cap:
$6.32B
Revenue:
-
Net Income/Loss:
$-173.59M
P/E Ratio:
-48.74
EPS:
-1.85
Net Cash Flow:
$-130.44M
1W Performance:
-0.88%
1M Performance:
-14.11%
6M Performance:
+28.10%
1Y Performance:
+59.93%
1-Day Range:
$88.48
$90.23
1-Week Range:
$87.25
$91.31
52-Week Range:
$55.25
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
AlphaCentric Advisors LLC Invests $716,000 in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent CFO Alexandra Balcom sells $891,879 in stock - Investing.com
Nuvalent's chief development officer Noci Darlene sells $442,980 in shares - Investing.com
Nuvalent's chief development officer Noci Darlene sells $442,980 in shares By Investing.com - Investing.com Australia
Nuvalent CFO Alexandra Balcom sells $891,879 in stock By Investing.com - Investing.com Australia
Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom Sells 10,000 Shares - MarketBeat
abrdn plc Sells 40,233 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
(NUVL) Technical Data - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Z - GuruFocus.com
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Sci - GuruFocus.com
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com
UBS Initiates Coverage of Nuvalent (NUVL) with Neutral Recommendation - MSN
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $195,500,000.00 in Stock - MarketBeat
Nuvalent sees $195.5 million stock sale by Deerfield Management - Investing.com
Nuvalent (NASDAQ:NUVL) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Where are the Opportunities in (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Shares Gap DownShould You Sell? - MarketBeat
Nuvalent CEO Porter sells shares worth $2.76 million - Investing.com
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) CEO Sells 27,000 Shares of Stock - MarketBeat
Nuvalent CEO Porter sells shares worth $2.76 million By Investing.com - Investing.com UK
AQR Capital Management LLC Has $1.01 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
AQR Capital Management LLC Sells 8,783 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
The Attractiveness of Investing In Nuvalent Inc (NUVL) is Growing - Knox Daily
Financial Metrics Unveiled: Nuvalent Inc (NUVL)’s Key Ratios in the Spotlight - The Dwinnex
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Nuvalent (NASDAQ:NUVL) Price Target to $125.00 - MarketBeat
Nuvalent executive sells over $500k in stock, buys $94.6k By Investing.com - Investing.com Australia
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Nuvalent executive sells over $500k in stock, buys $94.6k - Investing.com
Nuvalent CFO Alexandra Balcom sells shares worth over $1 million By Investing.com - Investing.com Canada
Nuvalent CFO Alexandra Balcom sells shares worth over $1 million - Investing.com
Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $508,700.00 in Stock - MarketBeat
Was there any good news for Nuvalent Inc (NUVL) stock in the last session? - US Post News
(NUVL) Long Term Investment Analysis - Stock Traders Daily
Marshall Wace LLP Buys 77,229 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent's SWOT analysis: promising cancer drug stock faces pivotal year - Investing.com India
Perceptive Advisors LLC Sells 234,377 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent's SWOT analysis: promising cancer drug stock faces pivotal year By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Cuts Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Driehaus Capital Management LLC Has $52.85 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent director Shair sells over $200k in company stock By Investing.com - Investing.com Australia
Nuvalent director Shair sells over $200k in company stock - Investing.com
Profund Advisors LLC Sells 4,915 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Fred Alger Management LLC Has $43.86 Million Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Samlyn Capital LLC Makes New Investment in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Samlyn Capital LLC Purchases Shares of 229,325 Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent’s $575 Million Common Stock Offering - Global Legal Chronicle
Nuvalent (NASDAQ:NUVL) Shares Down 5% - MarketBeat
Nuvalent: Promising Data Keeps Validating Pipeline And Platform (NASDAQ:NUVL) - Seeking Alpha
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Nov 01 '24 |
Sale |
88.60 |
5,000 |
442,980 |
33,300 |
| Balcom Alexandra | Chief Financial Officer |
Oct 31 '24 |
Option Exercise |
27.85 |
10,000 |
278,500 |
43,300 |
| Balcom Alexandra | Chief Financial Officer |
Oct 31 '24 |
Sale |
89.19 |
10,000 |
891,879 |
33,300 |
| Shair Matthew | Director |
Oct 28 '24 |
Sale |
91.73 |
2,000 |
183,468 |
224,522 |
| Flynn James E | Director |
Oct 22 '24 |
Sale |
97.75 |
2,000,000 |
195,500,000 |
8,670,512 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):